LondonBlocking one enzyme made a hidden cancer visible.
About half of Merkel cell carcinoma patients relapse after checkpoint drugs stop working.
Researchers expected the immune signal to run through cGAS-STING but found NF-κB driving it instead, in cell-line experiments.
ATR inhibitors are already in trials (NCT05947500) but remain unapproved for this use.
Sources: Nature